Navigation Links
INC Research and invivodata Announce ePRO Partnership
Date:3/4/2010

invivodata’s Regulatory Expertise Enhances CRO's Robust Global Service Offering

Raleigh, NC and Pittsburgh, PA (Vocus) March 4, 2010 -- INC Research®, Inc., a therapeutically focused contract research organization (CRO) with a process for delivering reliable results and invivodata®, inc., the industry leader in patient reported outcomes (PRO) solutions and services for global clinical research, today announced a partnership in which invivodata provides its ePRO solutions and services as a component of INC’s full service offering portfolio. The partnership has evolved from the successful execution of multiple international clinical trials in which INC Research and invivodata clinical service teams have delivered ePRO solutions and services to global biopharmaceutical customers.

INC Research has unrivaled expertise and a reputation for conducting global clinical development programs of the highest integrity. With its focus on providing its customers fit for purpose solutions, INC Research continually assesses industry developments to adopt proven technologies into their complete range of customized clinical trial services.

“We chose to partner with invivodata based on the integration of scientific and regulatory principles into their ePRO solution - elements critical in ensuring high patient compliance and reliable data,” said Alistair Macdonald, INC Research’s executive vice president, Strategic Development. “By leveraging our relationship with invivodata, we can continue to guide our customers through any regulatory changes that may affect their research decisions, especially in light of the recent publication of the FDA's final PRO Guidance.”

invivodata combines scientific and regulatory expertise with practical technology and proactive services that enable clinical trial sponsors to confidently determine the effectiveness of new medical products and therapies. invivodata scientists and regulatory experts have long contributed to industry meetings that helped shape PRO guidance and have provided expertise to clinical researchers making key decisions about their PRO strategies for global clinical development programs.

"Having collaborated on multiple international clinical trials to date, invivodata and INC Research have developed synergies between our teams that drive real-world efficiencies in clinical research and better equip our customers to manage their clinical development processes," said Doug Engfer, invivodata president and CEO. “We’re eager to continue building on our long-term relationship with INC Research, and to help maximize the value they deliver to global biopharmaceutical organizations.”

About invivodata inc.
invivodata combines behavioral science, information technology, and clinical research expertise to capture high quality clinical trial data directly from patients. invivodata’s electronic Patient Reported Outcomes (ePRO) solutions, which are based on over 20 years of research, deliver reliable patient self-reported data by driving patient compliance with the protocol and eliminating recall biases that plague paper-based self-report data. invivodata’s solutions include comprehensive trial-support services that facilitate the collection of ePRO data, web-based access to study data and operational reports that give researchers and sponsors visibility into study progress, and scientific and regulatory consulting on the use of PRO data in a regulated environment. invivodata’s solution has been used in more than 275 clinical programs and is the industry-leading ePRO system in delivering primary efficacy data for FDA drug approvals. invivodata inc. is a privately held company with global headquarters in Pittsburgh, Pa., USA; its European headquarters is in London, England; and its technology development center is in Scotts Valley, Calif., USA. For more information visit www.invivodata.com.

About INC Research® Inc.
INC Research is a therapeutically focused contract research organization with a high performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in therapeutic areas of specialty, and in innovative pediatric and women’s health trials. The company’s The Trusted Process® methodology and therapeutic foresight leads customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, North Carolina. For more information please visit www.incresearch.com.

# # #

Read the full story at http://www.prweb.com/releases/2010/03/prweb3683514.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. New Research Reveals Mechanism By Which TNFerade(TM) Suppresses Metastases
2. Sorting device for analyzing biological reactions puts the power of a lab in a researchers pocket
3. U.S. Government Awards DuPont, Partners with Technology Investment Agreement for Macroalgae-to-Biobutanol Research
4. New Source for Science Funding: BenchFly Pioneers Search for Research Program
5. Stem Cell Innovations to Provide Research and Assay Services to Agennix.
6. Sunlight Research(TM), Releases its Osiris Therapeutics Stem Cell Patent Report
7. No New Findings in Atrazine Study Promoted by Discredited Researcher, According to the Hudson Institute Center for Global Food Issues
8. Funds Boost Research into Causes, Interventions for Age-Related Cognitive Decline
9. Stephen Coles is Recognized by Continental Whos Who Among Health Care Research Professionals
10. febits miRBase 14 Geniom-Biochip Now With 58 Additional New Sequences Available for Cancer Research
11. Researchers gain detailed insight into failing heart cells using new nano technique
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
INC Research and invivodata Announce ePRO Partnership
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , ... of Cancer Research, London (ICR) and ... with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple ... as MUK nine . The University of ... is partly funded by Myeloma UK, and ICR will perform ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today ... designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) ... able to cross the cell membrane and bind intracellular STAT3 and inhibit its ...
(Date:10/10/2017)... ... 10, 2017 , ... For the second time in three ... Mentoring Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October ... US2020’s mission is to change the trajectory of STEM education in America by ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced the ... NIH to develop RealSeq®-SC (Single Cell), expected to be ... small RNAs (including microRNAs) from single cells using NGS ... the need to accelerate development of approaches to analyze ... "New techniques for measuring levels of mRNAs ...
Breaking Biology Technology:
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
Breaking Biology News(10 mins):